Inclusion Criteria:  Acute Myeloid Leukemia (AML) participants who have been prescribed oral Venetoclax tablets for the first time according to the approved label.  Exclusion Criteria:  Participants with contraindications to Venetoclax as listed on the approved local label. Participants receiving Venetoclax in clinical trials.